This record was last updated December 2, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2018-09-04; most recent amendment 2024-11-27.
Status change: Not Yet Recruiting → Recruiting2024-11-27